Table 3.
Overview of the literature for pulmonary metastasectomy for soft tissue sarcoma
| Reference | Institution | N | 5y OS (%) | Median OS (mo) | Proportion RPS (%) |
|---|---|---|---|---|---|
| Roth 1985 [98] | NCI, Bethesda, USA | 67 | 15 (est, for DFI>12 mo) | 30 (est, for DFI>12 mo) | N/A |
| Jablons 1989 [99] | NIH, Bethesda, USA | 63 | – | – | N/A |
| Lanza 1991 [100] | MDACC, Houston, USA | 24 | 18.5 | 22 | 15 |
| Casson 1992 [52] | MDACC, Houston, USA | 65 | 25.8 | 25 | N/A |
| Verazin 1992 [40] | RPCI, Buffalo, USA | 61 | 22 | 21 | N/A |
| Gadd 1993 [101] | MSCKK, New York, USA | 135 | 18 | 19 | 0 |
| Mentzer 1993 [102] | BWH, Boston, USA | 34 | 21 (4YS) | 26 | N/A |
| Saltzman 1993 [103] | UMH, Minnesota, USA | 23 | 71 | – | N/A |
| Ueda 1993 [104] | Osaka, Japan | 23 | 24.8 | – | N/A |
| Van Geel 1994 [105] | Rotterdam, Netherlands | 9 | – | – | N/A |
| Choong 1995 [106] | Mayo clinic, Rochester, USA | 214 | 40 | – | 0 |
| Van Geel 1996 [38] | Multi-institutional | 255 | 38 | – | 5.2 |
| Pastorino 1997 [37] | Multi-institutional | 1917 | 31 | – | N/A |
| Billingsley 1999 [39] | MSKCC, New York, USA | 138 | 46 (3YS) | 33 | N/A (9% of all sarcoma patients in used database) |
| Weiser 2000 [36] | MSKCC, New York, USA | 86 (repeated resections) | 36 | 42.8 | N/A |
| Canter 2007 [35] | MSKCC, New York, USA | 138 | 29 (DSS) | 30 | N/A |
| Rehders 2007 [30] | Hamburg, Germany | 61 | 25 | 33 | N/A |
| Liebl 2007 [107] | Hamburg, Germany | 42 | 40.5 | 66 | N/A |
| Chen 2009 [108] | Kyoto, Japan | 23 | 43 | 24 (est) | 9 |
| Smith 2009 [34] | RPCI, Buffalo, USA | 94 | 18 | 16 | 6 |
| Blackmon 2009 [33] | MDACC, Houston, USA | 147 | 26 | 35.5 | N/A |
| Stephens 2011 [32] | MDACC, Houston, USA | 81 (after chemotherapy) | 32 | 35.5 | N/A (44% non-extremity) |
| Nakamura 2011 [109] | Mie, Japan | 45 | 10.6 | N/A | N/A |
| Casiraghi 2011 [110] | Milan, Italy | 80 | 39 | N/A | N/A |
| Predina 2011 [111] | JKCC, Philadelphia, USA | 48 | 52 | 20.4 (DFS) | N/A |
| Hornbech 2011 [112] | Copenhagen, Denmark | 32 | 21.7 | 25.5 | N/A |
| Kim 2011 [113] | MGH, Boston, USA | 62 | 50.1 (including bone sarcoma) | 25 (including bone sarcoma) | N/A |
| Burt 2011 [31] | BWH, Boston, USA | 82 | 52 (LMS) | 70 (LMS) | 8.5 |
| Treasure 2012 [114] | Thames Registry, UK | 6256 | 15 | N/A | N/A |
| Schur 2014 [43] | Vienna, Austria | 46 | 32 | 45.3 | 19.6 (abdomen/pelvis) |
| Dossett 2015 [44] | Moffitt Cancer Center, Tampa, USA | 120 | – | 48 | N/A |
| Lin 2015 [41] | UCLA, Los Angeles, USA | 108 | 61 (LMS), 17 (LPS) | 35.4 | 6.5 |
| Chudgar 2017 [45] | MSKCC, New York, USA | 539 | 34% | 33.2 | 12 (RP/abdomen/pelvis) |
GISTs and bone sarcomas were excluded when possible.
OS, overall survival; RPS, retroperitoneal sarcoma; N/A, not available.